Watch live: announcement of the Nobel Prize in Physics 2016
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Click the video to watch the results live from the Nobel Prize Announcements 2016!
List view / Grid view
News
ESMO 2016: New data from Eisai’s oncology portfolio for halaven (eribulin), lenvima (lenvatinib) and kisplyx (lenvatinib)
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
European Pharmaceutical Review will of course keep you up to date with all the latest pharma news from the conference. Here's a preview snippet...
NICE recommends first drug for the Cancer Drugs Fund
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance which says osimertinib (Tagrisso, AstraZeneca) should be made available to some people with lung cancer through the Cancer Drugs Fund (CDF).
MedImmune out-licenses inflammatory diseases medicine to Allergan
3 October 2016 | By Niamh Louise Marriott, Digital Content Producer
MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb trial for Crohn’s disease (a chronic inflammatory disease of the intestines) and is...
Novartis’ global study shows 57% of psoriasis patients didn’t reach clear skin treatment goal
3 October 2016 | By Niamh Louise Marriott, Digital Content Producer
People with the autoimmune disease, psoriasis, also report that they face discrimination, humiliation, and mental illness...
AbbVie’s HCV regimen receives FDA breakthrough designation
30 September 2016 | By Niamh Louise Marriott, Digital Content Producer
For the investigational, pan-genotypic regimen of glecaprevir /pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C...
Infirst’s treatment for chronic wounds now available on NHS
30 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Granulox increases levels of oxygen at the wound bed, speeding up the rate of healing in wounds, venous leg ulcers, by 75% compared to standard care...
Long-term study shows less frequent and severe pancreatitis following gene therapy for LPLD
30 September 2016 | By Niamh Louise Marriott, Digital Content Producer
6 years after receiving a single treatment with gene therapy, patients with the debilitating genetic disease LPLD had 50% fewer episodes of pancreatitis...
Demand for Cherwell’s SAS Air Sampler Calibration service continues to rise year-on-year
30 September 2016 | By Cherwell Laboratories
Overall demand up by 15% with on-site calibrations showing most significant rise...
NICE recommends Novartis’ ankylosing spondylitis drug
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE are recommending it as an option to treat adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy...
Boehringer Ingelheim and ViraTherapeutics collaborate to boost immune-oncology pipeline
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Under the terms of the collaboration, Boehringer Ingelheim receives the right to acquire ViraTherapeutics after conclusion of Phase I clinical development...
Survey: Pharmaceutical Water Testing – Water For Injection (WFI)
28 September 2016 | By European Pharmaceutical Review
European Pharmaceutical Review invites you to participate in this brief survey on Pharmaceutical Water Testing for the chance to win one of 40+ Amazon Gift Cards ranging from €5 to €100!
Syrris creates Orb Pilot for effortless reaction scale-up
28 September 2016 | By Syrris
Syrris, a world leader in chemistry product innovation, is launching the Orb Pilot jacketed reactor this fall...
Moberg begins patient enrolment in US and Europe Phase 3 onychomycosis trials
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Approximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The prescription market is growing...
Bristol-Myers Squibb and Nektar Therapeutics to combine oncology therapies
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Bristol-Myers' Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression and NKTR-214 is an immuno-stimulatory therapy...
